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ARE CLINICAL CHARACTERISTICS ASSOCIATED WITH UPPER-EXTREMITY 
HYPERTONIA IN SEVERE ISCHAEMIC SUPRATENTORIAL STROKE?
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Objective: The primary goal of this study was to identify 
clinical risk factors, in addition to muscle weakness, for 
upper-extremity hypertonia in patients with severe ischaemic 
supratentorial stroke. The secondary goal was to investigate 
the time course of upper-extremity hypertonia in these pa-
tients during the first 26 weeks post-stroke.
Design: Inception cohort.
Patients: Forty-three consecutive patients with an acute 
ischaemic supratentorial stroke and an initial upper-extre-
mity paralysis admitted to an academic hospital.
Main outcome measures: Primary outcome: hypertonia as-
sessed by the Ashworth scale at week 26 post-stroke. Poten-
tial risks factors: motor functions assessed by the upper-
extremity subscore of the Fugl-Meyer motor assessment, 
Barthel Index at week 1, consciousness, sensory disturban-
ces, apraxia, neglect, and hyper-reflexia. Secondary outco-
me: time course of upper-extremity hypertonia by assessing 
its prevalence at 6 consecutive moments post-stroke during 
a follow-up period of 26 weeks.
Results: Twenty-five patients (63%) developed hypertonia 
during the follow-up period of 26 weeks. During this period, 
the prevalence of hypertonia followed a rather dynamic 
course, with cases of early, transient and late hypertonia. 
Univariate analyses yielded none of the selected clinical cha-
racteristics as significantly associated with hypertonia. 
Conclusion: Despite the high incidence of hypertonia (63%) 
observed, none of the selected clinical characteristics could 
be identified as a risk factor for hypertonia. 
Key words: stroke, upper extremity, hypertonia, incidence, risk-
factors.
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INTRODUCTION
Spasticity is a characteristic component of the upper motor 
neurone syndrome in the post-acute and chronic phases of 
stroke. Spasticity develops in about 20–40% of all stroke 
survivors, usually within 3 months post-stroke (1–5). In the 
upper extremity, spasticity may cause difficulty with basic 
arm and hand abilities, such as reaching and grasping, as well 
as with many more complex activities of daily living (ADL) 
(6–8). In the acute and post-acute phases after stroke, recurrent 
negative reinforcement in attempts to use the affected arm can 
lead to so-called “learned disuse”, in particular when spastic 
antagonists counteract selective voluntary muscle activity (9). 
Moreover, in the long-term, untreated spasticity can lead to 
secondary complications, such as changes in the visco-elastic 
properties of the musculo-tendinous apparatus (stiffness), loss 
of muscle length (contractures), and pain, which may further 
impede the functional use of the upper extremity (3, 10).
The precise relationship between spasticity elicited by pas-
sive tendon or muscle stretch and active movement capacity, 
however, remains unclear. As a consequence, it is not clear 
whether reduction of spasticity will always improve active 
motor functions and dexterity. A systematic review of the 
treatment of post-stroke upper-extremity spasticity by focal 
neuronal or neuro-muscular blockade revealed the potential 
efficacy of such treatments in reducing hyper-reflexia, muscle 
tone, and in improving passive range of joint motions (11), yet, 
functional benefits could not be convincingly demonstrated. 
Generally, functional effects of spasticity treatment seem to 
depend highly on a critical selection of subjects, individualized 
goal setting, and appropriate selection of outcome measures 
(12, 13). Patients after severe stroke with a low potential for 
motor recovery in particular may profit from a pro-active 
treatment approach to prevent disabling spasticity and the 
functional consequences of secondary complications, such 
as muscles stiffness, contractures and pain. Benefits can be 
achieved with regard to activities such as dressing, bathing and 
grooming, as well as with regard to limb positioning, cosmetic 
appearance and comfort (12, 13). Against this background, it 
seems clinically relevant to assess, besides the probability of 
motor recovery, the risk of developing spasticity in the indi-
vidual patient early after stroke. 
However, although motor recovery can be predicted reaso-
nably well by clinical assessment (14), early recognition of 
the risk of developing spasticity based on clinical characte-
ristics is much more difficult and the literature does not really 
support clinical reasoning. Because the clinical assessment 
of spasticity measures resistance against passive stretch (hy-
pertonia), it cannot distinguish between the neural (reflexive) 
mechanisms, and the secondary (intrinsic) changes in muscle 
properties. Studies on the risk factors for post-stroke hypertonia 
are also scarce. Besides a recently published cohort study by 
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Leathly et al. (4), no other studies are available in (sub-)acute 
stroke patients. In stroke survivors, Leathly et al. (4) found 
a moderate association of both muscle weakness and a low 
Barthel Index (BI) (15) on day 7 post-stroke with hypertonia 
at 12 months post-stroke. Based on clinical experience, some 
authors have suggested the importance of sensory impairments, 
visuospatial deficits, and apraxia for developing hypertonia 
(16, 17). However, these disorders were not identified as risk 
factors in the study by Leathly et al. (4), which might have 
been due to the relatively low number of cases with hyperto-
nia (36%). Against this background, we conducted a cohort 
study including only patients with an initial paralysis of the 
upper extremity after supratentorial stroke to maximize the 
likelihood of observing hypertonia and, thus, to optimize the 
chance of identifying additional risk factors for post-stroke 
upper-extremity hypertonia. As a secondary goal, we studied 
the time course of upper-extremity hypertonia by assessing 
its prevalence at 6 consecutive moments post-stroke during a 
follow-up period of 26 weeks. 
MATERIAL AND METHODS
Patients 
As part of a larger study on the value of motor-evoked potentials (MEP) 
in predicting motor and functional outcome after stroke (18), 43 con-
secutive acute patients with an ischaemic supratentorial stroke were 
recruited during a 1.5-year period. These patients were admitted to the 
Department of Neurology at the Radboud University Medical Centre 
Nijmegen. The diagnosis of stroke was made clinically by a neurologist 
according to the World Health Organization (WHO) clinical criteria 
(19) and confirmed by computerized tomography (CT) scan. 
Only patients presenting with stage I of the upper extremity accord-
ing to Brunnstrom (20) (i.e. no tone and no voluntary muscle activity at 
the elbow, wrist or finger flexors) at day 1 were included within 7 days 
post-stroke. Patients with a poor prognosis for survival (loss of consci-
ousness, severe CT abnormalities, and severe co-morbidity) as well as 
patients with severe pre-existing impairments of the upper extremity 
of any type (e.g. rheumatic deformities, contractures) were excluded. 
Because all patients had to undergo transcranial magnetic stimulation 
to record MEPs, those with a history of craniotomy, epilepsy, cardiac 
prosthetic valve or pacemaker implantation, or severe polyneuropathy 
were also excluded. The local ethics committee approved the study 
protocol and written informed consent was obtained from all patients 
before study entry. 
Each patient received “best medical treatment” according to the 
guidelines of the Netherlands Society of Neurology, including a multi-
disciplinary initial rehabilitation approach. This approach ensured that 
each patient received physiotherapy to maintain optimal passive and 
active range of motion of all upper-extremity joints from day 1 post-
stroke. However, for the first 3 weeks post-stroke, no specific therapy 
was initiated aimed at facilitation of arm-hand function recovery.
Potential risk factors
Clinical assessment. Within the first 24 hours after stroke the treating 
neurologist assessed all patients with regard to initial motor functions, 
muscle tone and level of consciousness. All consecutive clinical as-
sessments of motor, sensory, and cognitive functions were performed 
at weeks 1, 2, 3, 6, 12 and 26 post-stroke by a rehabilitation specialist 
(HH). Motor functions were assessed according to the upper limb 
subset of the Fugl-Meyer Motor Assessment (FMA) (20). A selected 
hand motor score was derived from the FMA, which consisted of the 
7 original hand items of the FMA with a maximum score of 14 points. 
Early hand motor function recovery was defined as any change in the 
FMA hand score within the first 3 weeks post-stroke.
Sensory deficits were assessed by clinical examination of light touch, 
pinprick, and vibration sense of the hemiplegic arm. Proprioception 
was assessed by the “thumb-finding test” (21). Sensory deficit was 
ultimately recorded on a binary scale as either “absent” or “present” 
based on reproducible differences in at least 2 sensory modalities 
compared with the non-paretic arm. Biceps and triceps tendon reflexes 
were quantified according to the Mayo Clinic scale for tendon reflex 
assessment (range –4 to +4) (22). Hyper-reflexia was considered 
present if the tendon reflex on the paretic side was ≥+1.
Neglect was defined as the inability to detect, attend to, or respond 
to stimuli located on the contra-lesional side of body or action space 
(23). Apraxia was defined as the inability to perform previously learn-
ed skilled acts, despite sufficient comprehension, motor capacity, 
and sensation. Both the existence of neglect and apraxia was based 
on clinical observations of the patient’s ADL performances by the 
nursing staff, the treating neurologist, and the consulting rehabilitation 
physician within the first 3 weeks post-stroke. Neglect and apraxia 
were considered present if symptoms were witnessed by at least 2 of 
these 3 observers. 
Finally, ADL performances were assessed with the BI (15). Consis-
tent with Leathly et al. (4), the BI score at the first week post-stroke 
was considered as a potential risk factor.
Outcome assessment. Hypertonia was clinically assessed by grading 
muscle tone through the Ashworth scale (AS) (24). Muscle tone was 
assessed within the first 24 hours post-stroke and consecutively at 
weeks 1, 2, 3, 6, 12 and 26 post-stroke under standardized test con-
ditions by a rehabilitation specialist (HH). The patients lay supine or 
sat in a comfortable sitting position with their forearms supinated and 
resting on a horizontal plane. Patients were instructed to completely 
relax while their affected elbows and wrists were passively moved 
throughout the maximal range in both flexion and extension direc-
tions. Passive extension of the patient’s elbow was performed during 
approximately one second by counting “one thousand and one” while 
the forearm was held just proximal to the wrist. When the elbow was 
extended, the upper arm was stabilized just proximal to the elbow. 
Passive extension of the patient’s wrist was also performed during 
approximately one second while the hand was held just proximal to 
the metacarpo-phalangeal joints and the forearm just proximal to the 
wrist. Muscle tone was quantified according to the criteria outlined 
by Ashworth (24) (grades 0–4). Clinically relevant hypertonia was 
operationally defined as an AS score equal to or greater than 2 in at 
least one joint.
Data analysis 
From 2×2 contingency tables, positive and negative predictive values 
for each of the potential risk factors with their 95% confidence interval 
were calculated. In addition, to test the association of gender with 
hypertonia, Pearson’s χ2 analysis was performed. The required 2-tailed 
significance level was set at 0.05. For the ordinal outcome measure 
BI at week 1 post-stroke, the Mann-Whitney U test was performed 
to assess the association between the BI and hypertonia. Again, the 
required 2-tailed significance level was set at 0.05. 
In case of positive outcome of the univariate analysis, multiple 
backwards logistic regression was planned to determine the explained 
variance by each characteristic with regard to hypertonia, independent 
of its possible association with other characteristics.
All analyses were performed using the Statistical Package for the 
Social Sciences (SPSS version 11). 
RESULTS
Patient characteristics and time course of post-stroke hypertonia
Two patients died within the first 2 weeks post-stroke. Both 
continued to have a flaccid paralysis of the upper extremity 
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from clinical presentation. Another patient was excluded from 
the study at week 13 because of poor prognosis for survival 
after he had a recurrent stroke. Thus, 40 patients, 20 women 
and 20 men, completed the study. The clinical characteristics of 
these 40 patients are shown in Table I. Sixteen (40%) patients 
had had a previous stroke, whereas 24 (60%) patients had had 
a first-ever stroke. 
The highest estimated AS scores in our patients were 0 
(n=9), 1 (n = 6), 2 (n = 8), 3 (n = 12), and 4 (n = 5). If clinical 
hypertonia was defined as AS ≥2, 25 (63%) patients developed 
hypertonia at any time post-stroke. In 20 patients hypertonia 
developed within the first 6 weeks post-stroke, and in 10 
(25%) patients even within the first 3 weeks post-stroke. This 
“early” (≤3 wks) hypertonia was not correlated with previous 
stroke (Fisher's exact p = 0.48). We identified 16 hypertonic 
patients at 6 months who were not initially hypertonic, as well 
as 3 patients with normal muscle tone at 6 months who were 
initially hypertonic. Fig. 1 illustrates how the prevalence of 
hypertonia evolved in our study sample. 
In 12 patients, recovery of hand motor function was present 
at week 26 post-stroke. In the group with persistent hypertonia, 
7 (33%) patients showed any recovery of hand motor function, 
whereas in the group without hypertonia 5 patients showed 
such recovery (26%). Fig. 2 illustrates the FMA-hand scores 
at week 26 post-stroke in both the patients with and those 
without persistent hypertonia.
Potential risk-factors for post-stroke hypertonia
Because, from a clinical point of view, we were most interested 
in predicting persistent hypertonia, we considered hypertonia 
at week 26 post-stroke as the primary outcome. In univariate 
analyses, all associations between hypertonia at week 26 and 
the potential risk factors were low and statistically not signifi-
cant. Table II shows the positive and negative predictive values 
with their 95% confidence intervals for all factors. Positive 
predictive values varied from 0.52 to 0.68 and the negative 
values from 0.33 to 0.62. 
In addition, 10 females and 12 men suffered from hypertonia 
at 26 weeks post-stroke. In both patients with and those without 
hypertonia the median BI at week 1 post-stroke was 2 (inter-
quartile range 0–4). There was no association between gender 
and hypertonia (χ2 0.404, p = 0.525) and neither between the 
BI at week 1 and hypertonia (p = 0.93). Changing the defini-
tion of persistent hypertonia into AS ≥2 at week 12 or week 6 
post-stroke yielded similar results. Even if clinically relevant 
hypertonia was defined as AS ≥1, or if hypertonia at any time 
post-stroke was used as the primary outcome, no association 
with the potential risk factors could be demonstrated. 
DISCUSSION
In this study a sample of patients with initial paralysis of the 
upper extremity caused by ischaemic supratentorial stroke was 
included to optimize the chance of identifying risk factors, ad-
ditional to muscle weakness, for early or persistent hypertonia. 
The observed overall incidence of hypertonia within 6 months 
post-stroke in this group was 63%. In comparison, Sommerfeld 
et al. (5) found a 24% overall incidence of hypertonia within 3 
months in a hospital-based cohort of patients with acute stroke 
a first-ever ischaemic stroke. Other studies on stroke-related 
hypertonia mainly reported prevalences instead of incidences, 
varying from 19% to 39% of the hospitalized stroke popu-
lation at large (4–6). Hence, our patient sample was clearly 
Table I. Characteristics of the 40 patients
Characteristics n
Gender Female 20
Male 20
Stroke history First ever 24
Previous 16
Lesion side Left 22
Right 18
Median age, years (interquartile range) 68 (59–77)
Median Barthel Index on admission (IQ range) 0 (0)
Fig. 2. Fugl-Meyer Motor Assessment (FMA) hand score at 26 weeks 
post-stroke in patients with (  ) and without (  ) persistent hypertonia.
Fig. 1. Prevalence of post-stroke hypertonia during the first 26 weeks 
post-stroke. Patients developing hypertonia at week 1 (  ), week 2 (  ), 
week 6 (  ), week 12 (  ), and week 26 post stroke (  ).
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different from those in previous studies. It was restricted to a 
homogeneous subgroup of the most severely affected survivors 
from ischaemic supratentorial stroke, i.e. those with an initial 
paralysis of the upper extremity. The severity of stroke is also 
evident from the finding that all patients had an initial BI of 0. 
Based on the observed incidence in this study, this subgroup 
of stroke patients with initial paralysis of the upper extremity 
apparently has a substantial chance of developing hypertonia 
within 6 months post-stroke.
Yet, even in this severely affected group, we could not 
identify any of the selected clinical characteristics as a sig-
nificant risk factor for early or persistent hypertonia. Even 
hyper-reflexia, which is regarded by many clinicians as a sign 
of “spasticity”, was not significantly associated with the AS 
in this study. This finding is corroborated by several electro-
physiological studies that have shown dissociations between 
hyper-reflexia and hypertonia, indicating that phasic and tonic 
stretch reflexes are controlled differently by the central nervous 
system (2, 5). However, it might also reflect the fact that the 
AS is unable to distinguish between neural mechanisms (hyper-
reflexia) and secondary intrinsic changes in muscle properties 
(contracture). As for sensory or cognitive deficits, our data 
do not underscore the clinical notion that loss of sensibility, 
neglect, or apraxia may increase the risk of developing post-
stroke upper-extremity hypertonia. These findings are consis-
tent with those of Patano et al. (25), who could not find any 
differences in sensory disturbances, aphasia, or visuospatial 
neglect between patients with prolonged muscular flaccidity 
and those with hypertonia in the subacute phase (2–6 months) 
post-stroke. Hence, as yet, only a modest association between 
early muscle weakness and chronic hypertonia has been found 
by Leathly et al. (4).
The secondary goal of this study was to explore the time 
course of upper-extremity hypertonia during the first 26 weeks 
post-stroke in patients with initial paralysis. Although it is 
generally assumed that muscle tone increases from flaccidity 
in the acute phase of stroke to various degrees of hypertonia in 
the long term (1, 2, 26), the patients with early (25% within 3 
weeks post-stroke), transient (10%), or late (15%) hypertonia 
in our cohort did not fit within this general idea. Sommerfeld 
et al. (5) reported hypertonia within the first week post-stroke 
in 21% of their acute hospitalized patients as well. In contrast 
to the opinion of others (27), in our study early hypertonia was 
not correlated with previous stroke. In 3 patients who develop-
ed hypertonia within 6 weeks post-stroke, muscle tone had 
normalized at 26 weeks, perhaps related to neural plasticity. At 
26 weeks we identified another 6 patients in which hypertonia 
developed only after the third month post-stroke. It seems 
likely that secondary intrinsic changes in muscle properties 
contributed to this late hypertonia (28).
At 26 weeks post-stroke, we did not find any difference 
in motor or functional recovery between patients with and 
those without hypertonia, which may be due to the fact that 
the majority of our patients ended up with a non-functional 
paralytic arm and hand. The unique influence of hypertonia 
on motor impairments and ADL performances is, no doubt, 
difficult to assess in a subgroup of patients with initial para-
lysis with such a poor chance of motor recovery. In addition, 
specifically patients with severe stroke may suffer from various 
other problems of, for example, mood, cognition, vision, and 
sensation, which may contribute to their overall disability. 
Lastly, the BI is probably not the best measure to assess ADL 
performances related to arm and hand function. When, for 
instance, hypertonia causes pain or discomfort or problems 
with arm positioning, dressing, or hygiene control, treatment 
that reduces hypertonia and prevents secondary complications 
may greatly benefit the patient on a functional level (12, 13), 
although such benefit does not need to be reflected in a change 
in the BI score.
One of the possible limitations of this study is that upper-
extremity hypertonia was clinically assessed using the AS, 
whereas instrumented analysis of electromyographic (EMG) 
and force signals from the upper-extremity muscles on passive 
stretching might have allowed better discrimination between 
active (i.e. contractions) and passive (i.e. stiffness) contribu-
tions to muscular resistance (3, 29). However, instrumented 
tests are not yet available for routine clinical application, which 
is the reason that the Ashworth and modified AS are still the 
most commonly used measures of adult spasticity in clinical 
practice. The AS are most frequently used as primary outcome 
measures in intervention studies as well, and other scales, such 
as the tone assessment scale, can be regarded as modifications 
of the AS. All these measures are equally reliable regarding 
muscle tone assessment of the upper extremity (30). Overall, 
there is a reasonable association between the (modified) AS 
and EMG responses in patients with hemiparetic stroke (31), 
which does not preclude a significant contribution of passive 
muscle properties to (particularly late) hypertonia.
Table II. Association between potential risk factors and hypertonia 
(HT) at 26 weeks post-stroke
With 
HT 
(n)
Without 
HT
(n)
PPV and NPV (95% CI)
Unconsciousness at stroke
Present 18 14 PPV 0.56 (0.38–0.74)
Absent 4 4 NPV 0.50 (0.35–0.97)
Sensory disturbances
Present 16 15 PPV 0.52 (0.34–0.70)
Absent 6 3 NPV 0.33 (0.07–0.59)
Hyper-reflexia
Present 17 13 PPV 0.57 (0.40–0.74)
Absent 5 5 NPV 0.50 (0.19–0.81)
Apraxia
Present 11 7 PPV 0.68 (0.49–0.87)
Absent 11 11 NPV 0.50 (0.28–0.72)
Neglect
Present 19 13 PPV 0.58 (0.41–0.75)
Absent 3 5 NPV 0.62 (0.33–0.91)
Early hand motor recovery
Absent 19 16 PPV 0.54 (0.37–0.71)
Present 3 2 NPV 0.40 (0.05–0.75)
PPV: Positive predictive values; NPV: Negative predictive values; 
CI: confidence intervals.
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Another limitation of our study may have been a lack of 
power to identify risk factors for upper-extremity hypertonia 
due to the still limited number of patients. We included merely 
patients with initial paralysis to optimize the risk of post-stroke 
hypertonia. This subgroup comprises only 19–30% of the stro-
ke population at large and has a high risk of post-stroke death 
(62%) (32). As a result, the inclusion rate was relatively low in 
just one academic hospital. However, 40 patients would have 
been sufficient to discriminate a moderate from an “absent” 
association between hypertonia and any clinical determinant 
(setting a at 0.05 and 1-b at 0.80). Hence, larger studies of 
high-risk patients will be needed to include the number of 
subjects to identify “weak” but significant associations.
In conclusion, the present study showed that a subgroup of 
patients with initial paralysis of the upper extremity apparently 
has a substantial chance of developing hypertonia at any time 
post-stroke. The observed incidence over the 26-week follow- 
up period was 63%. The prevalence of upper-extremity 
hypertonia during the first 26 weeks post-stroke followed a 
rather dynamic course, with cases of early, transient and late 
hypertonia. Even in this selected study sample with a high 
incidence of hypertonia, we could not identify any of the 
selected clinical characteristics as a risk factor for transient 
or persistent hypertonia. Unlike the stroke population in gene-
ral, in patients with severe stroke and initial upper-extremity 
paralysis, hypertonia appeared not to be associated with motor 
or functional recovery of the affected arm.
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